The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2021 | Novel therapies for T-cell lymphoma
Steven Horwitz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, summarizes advances in in T-cell lymphoma therapies. Various novel drugs such as valemetostat, a EZH1/2 dual inhibitor, ruxolitinib, a JAK1/2 inhibitor, and duvelisib, a PI3K inhibitor, have all shown durable responses in preliminary clinical trials and are promising treatments. Further research will elucidate whether these therapies are active in specific or a wide range of subtypes of T-cell lymphoma. Novel combination therapies such as brentuximab vedotin plus CHP (cyclophosphamide, doxorubicin and prednisone), romidepsin plus CHOP (CHP plus vincristine), or romidepsin plus lenalidomide were additionally discussed. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
